DP
Daewoong Pharmaceutical at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Daewoong Pharmaceutical brings 2 presentations to ObesityWeek 2026 in National Harbor. Its posters present new long-acting ways to deliver semaglutide, with first-in-human pharmacokinetics and safety data for a microneedle patch. A low-burst monthly depot shows sustained exposure in people and efficacy in obese rats.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
DP Daewoong Pharmaceutical Seoul, South Korea | |
Drug maker developing long-acting forms of semaglutide, including a microneedle patch and a monthly depot. | Poster Sat Nov 14 7:30pm–8:30pm Low-Burst Monthly Semaglutide Depot Achieves Sustained Human Exposure and DIO Rat Efficacy Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Pharmacokinetics and Safety of a Semaglutide Microneedle Patch in a First-in-Human Study Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology |
Find decision makers at Daewoong Pharmaceutical
Tell us what you sell and we’ll find the people at Daewoong Pharmaceutical most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction